Nevertheless, in light of the fact that PCSK9 is an important target for the prevention and treatment of atherosclerosis and lipid homeostasis [6], the clinical effect of additional PCSK9 inhibition during cilostazol treatment warrants further investigation. The gene discussed is PCSK9; the disease is atherosclerosis.